The Custodian  ·  A Founder's Story  ·  Session One

You're About to Pay for a Decision You Haven't Made Yet.

The decision that cost you most probably felt right when you made it.

The Setup

Sarah is a founder. Three years into developing a wearable cardiac monitoring device that detects arrhythmia patterns missed by standard 24-hour Holter monitors. One active pilot site — a regional hospital — is generating early clinical data. A cardiology practice that was an early relationship is no longer in play. A small team. Pre-seed capital almost exhausted.

She's technically rigorous. She understands the clinical problem deeply. She believes the device works because the data says it works.

She agreed to a 30-minute conversation because a mutual contact said it would be worth her time. She doesn't know what the Custodian is.

Step One — The Recall

Custodian Before I show you anything — I want to ask you something first. In the last 18 months, is there a decision you made that felt completely right when you made it — you had good reasons, you committed fully — and then somewhere down the line it cost you in a way you didn't see coming?
Sarah Yes. About a year ago I decided to pursue the hospital pilot first rather than the cardiology practice. The hospital had more patients, more prestige, and the clinical lead was enthusiastic. It felt like the faster path to meaningful data. We spent eight months navigating their procurement process, their IT security requirements, their ethics committee. By the time we were operational the cardiology practice had moved ahead with a competitor device — not better than ours, just easier to deploy. We lost the relationship we should have protected.
Custodian Did you have good reasons when you made the decision?
Sarah Yes. The patient volume made sense. The clinical credibility made sense. The logic was sound.
Custodian So you weren't careless.
Sarah No.
Custodian And you weren't short on experience in the clinical space.
Sarah No. I knew how hospitals work. I thought I'd accounted for the procurement complexity.
Custodian Then here's the question I actually want you to sit with. What if you couldn't have seen it? Not because you missed a data point — but because at the moment you made that decision, those consequences were structurally invisible to your picture of the situation.

Sarah goes quiet. She's been carrying this as a planning failure. That framing just shifted.

Step Two — Causality

Custodian When you chose the hospital, your picture of the decision was built from clinical logic — patient volume, data quality, institutional credibility. It was a good picture. But here's what that picture couldn't show you: a pre-seed medical device company running an eight-month hospital procurement cycle is not just slow. It's invisible to the market. While your attention and your team's energy were entirely consumed by one institution's internal process, the cardiology practice — your most accessible early adopter — experienced your absence as disinterest. They didn't wait. They couldn't afford to.
Sarah So it's not that I made the wrong clinical choice.
Custodian Correct. The hospital was the right clinical environment for your data. But your picture was built from clinical logic alone. It had no data from the commercial consequence of what an eight-month procurement cycle does to a relationship that isn't being actively managed. That consequence lived outside the frame you were using to evaluate the decision.
Sarah I'm not thinking badly. I'm thinking from the wrong frame.
Custodian You're thinking from the only frame you had. Which is exactly the problem.
"The cost wasn't inevitable. It was a visibility problem. And visibility problems have structural solutions."

Step Three — The Restructuring

Custodian If you had seen that consequence clearly before you committed — not as a vague risk, but as a specific lived cost: eight months of organisational attention consumed, a competitor gaining the relationship you'd built, and a reference site lost before your data was ready — what would you have done?
Sarah I still would have pursued the hospital. The data quality matters for regulatory submission. But I would have assigned someone explicitly to keep the cardiology practice warm. Regular touchpoints, shared interim data, something that said we haven't forgotten you. I would have treated it as a relationship that needed tending, not a site that could wait.
Custodian So you wouldn't have cancelled the hospital.
Sarah No. But I would have structured the commitment so it didn't consume everything.
Custodian And the cost?
Sarah Avoidable. Entirely.
Custodian Notice what just happened. Your decision wasn't wrong. The timing of when you encountered the consequences was the problem. You paid a significant price after the commitment — a price you could have accounted for before it, if the consequences had been visible while they were still actionable.

Step Four — A Live Commitment

Custodian You're approaching a seed raise with clinical data but no regulatory pathway locked. What's the biggest uncommitted decision sitting on your desk right now?
Sarah How to position the device for investors. Our data shows the device catches arrhythmias that Holter monitors miss. The clinical story is clear. But investors keep asking about the market size, and the arrhythmia monitoring market as currently defined isn't large enough to excite them. I'm being pushed toward positioning this as a broader cardiac intelligence platform — AI-driven, continuous, population-level insights. It's a much bigger story. But I'm not sure what I break if I lead with a vision the device can't yet support.
Custodian That's exactly what the Custodian is built for. Let's map that commitment now — before you walk into the next investor conversation.

Consequences surfaced — before commitment

  1. The 510(k) pathway for a targeted arrhythmia monitor is navigable. The regulatory pathway for a cardiac intelligence platform is categorically different — longer, more expensive, and requiring clinical evidence you don't yet have. Committing to the platform story in investor materials creates pressure to pursue the harder regulatory path before you have the resources to execute it.
  2. A cardiac intelligence platform story requires regulatory framing, reimbursement pathways, and data infrastructure your current device doesn't yet support. The investors who fund that story will arrive at their first board meeting expecting progress against a platform thesis. When your next six months are spent on arrhythmia monitoring pilots and a 510(k) submission, the gap between what was sold and what is being built becomes a board-level credibility problem — before you've had time to earn the platform.
  3. Clinical champions who adopted your device because it solves a specific, well-defined arrhythmia problem will find the platform positioning confusing and potentially threatening to their own institutional narratives. The cardiologists who are your current advocates were not hired to champion AI platforms. Shifting your story repositions what they signed up for — and risks losing the clinical relationships your regulatory submission depends on.
Custodian Were any of those visible to you before now?
Sarah The first one — I knew the regulatory pathway was more complex. But I was telling myself I'd cross that bridge later once the funding was secured. The board credibility gap and the clinical champion problem? No. I hadn't thought about what the platform story does to the people who adopted the device for the specific thing it does today. Those are the relationships I can't afford to damage before submission.
Custodian Does it change what you're about to do?
Sarah Completely. I was going to lead with the platform story in my next two investor meetings. Now I need a bridge — something that says here is the specific clinical problem we solve today, here is the evidence that we solve it better than anything else, and here is the architecture that makes platform capabilities the natural next step. Not a leap I'm asking investors to fund before the foundation exists.
Custodian You just moved a cost from after your raise to before it.

Sarah sits back.

Sarah That's what this does.
Custodian Every time. For every commitment — before you make it, not after you've paid for it.

What Just Happened

Sarah didn't receive a warning. She wasn't told to slow down or think harder. The Custodian didn't conflict with her identity as someone who moves fast, builds rigorously, and backs her clinical instincts.

It did something structurally different: it moved the cost from after the commitment to before it. The consequence was always going to happen. The Custodian changed when she encountered it.

She's not slowing down. She's not making fewer commitments. She now encounters the consequences of her decisions before she pays for them — while they're still visible, while they're still actionable, while the cost is still a choice rather than a surprise.

In medical devices, that distinction matters more than almost anywhere else. The commitments that compound against you — the regulatory pathway chosen too early, the clinical champion alienated by a positioning shift, the investor expectation set before the product can meet it — don't arrive as single catastrophic events. They arrive as accumulating friction that makes every subsequent decision harder. Encountering them before they accumulate is not a luxury. It's the condition for getting through the crossing.

Choose Your Path

Sarah's story continues across two more sessions. Or bring your own uncommitted decision — and see what the Custodian surfaces before the cost arrives.

Run My Own Uncommitted Decision No pitch. No slides. Your decision, live. Continue to Session Two Sarah's first senior hire with seed capital. The profile looks right. The timing makes it structural.